A combined phase I and II open label study on the effects of a seaweed extract nutrient complex on osteoarthritis
Stephen P Myers1,2, Joan O’Connor1,2, J Helen Fitton3, Lyndon Brooks4, Margaret Rolfe4, Paul Connellan5, Hans Wohlmuth2,5,6, Phil A Cheras1,2, Carol Morris51NatMed-Research, 2Centre for Health and Wellbeing, 4Graduate Research College, 5Centre for Phytochemistry and Pharmacology, 6Medi...
Guardado en:
| Autores principales: | , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Dove Medical Press
2010
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/1b3fb350814c4649a4fcf61fe7e88109 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:1b3fb350814c4649a4fcf61fe7e88109 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:1b3fb350814c4649a4fcf61fe7e881092021-12-02T00:33:52ZA combined phase I and II open label study on the effects of a seaweed extract nutrient complex on osteoarthritis1177-54751177-5491https://doaj.org/article/1b3fb350814c4649a4fcf61fe7e881092010-02-01T00:00:00Zhttp://www.dovepress.com/a-combined-phase-i-and-ii-open-label-study-on-the-effects-of-a-seaweed-a3963https://doaj.org/toc/1177-5475https://doaj.org/toc/1177-5491Stephen P Myers1,2, Joan O’Connor1,2, J Helen Fitton3, Lyndon Brooks4, Margaret Rolfe4, Paul Connellan5, Hans Wohlmuth2,5,6, Phil A Cheras1,2, Carol Morris51NatMed-Research, 2Centre for Health and Wellbeing, 4Graduate Research College, 5Centre for Phytochemistry and Pharmacology, 6Medicinal Plant Herbarium, Southern Cross University, Lismore, NSW, Australia; 3Marinova Pty Ltd, Hobart, Tasmania, AustraliaBackground: Isolated fucoidans from brown marine algae have been shown to have a range of anti-inflammatory effects.Purpose: This present study tested a Maritech® extract formulation, containing a blend of extracts from three different species of brown algae, plus nutrients in an open label combined phase I and II pilot scale study to determine both acute safety and efficacy in osteoarthritis of the knee. Patients and methods: Participants (n = 12, five females [mean age, 62 ± 11.06 years] and seven males [mean age, 57.14 ± 9.20 years]) with a confirmed diagnosis of osteoarthritis of the knee were randomized to either 100 mg (n = 5) or 1000 mg (n = 7) of a Maritech® extract formulation per day. The formulation contained Maritech® seaweed extract containing Fucus vesiculosis (85% w/w), Macrocystis pyrifera (10% w/w) and Laminaria japonica (5% w/w) plus vitamin B6, zinc and manganese. Primary outcome was the average comprehensive arthritis test (COAT) score which is comprised of four sub-scales: pain, stiffness, difficulty with physical activity and overall symptom severity measured weekly. Safety measures included full blood count, serum lipids, liver function tests, urea, creatinine and electrolytes determined at baseline and week 12. All adverse events were recorded.Results: Eleven participants completed 12 weeks and one completed 10 weeks of the study. Using a multilevel linear model, the average COAT score was reduced by 18% for the 100 mg treatment and 52% for the 1000 mg dose at the end of the study. There was a clear dose response effect seen between the two treatments (P ≤ 0.0005) on the average COAT score and each of the four COAT subscales (pain, stiffness, difficulty with physical activity and overall symptom severity) (P ≤ 0.05). The preparation was well tolerated and the few adverse events were unlikely to be related to the study medication. There were no changes in blood parameters measured over the course of the study with the exception of an increase in serum albumin which was not clinically significant.Conclusion: The seaweed extract nutrient complex when taken orally over twelve weeks decreased the symptoms of osteoarthritis in a dose-dependent manner. It was demonstrated to be safe to use over the study period at the doses tested. The efficacy of the preparation now needs to be demonstrated in a phase III randomized controlled trial (RCT). Australian and New Zealand Clinical Trials Register: ACTRN12607000229471. Keywords: fucoidan, osteoarthritis, complementary medicine, inflammation, TNF alpha Stephen P MyersJoan O’ConnorJ Helen Fittonet al.Dove Medical PressarticleMedicine (General)R5-920ENBiologics: Targets & Therapy, Vol 2010, Iss default, Pp 33-44 (2010) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Medicine (General) R5-920 |
| spellingShingle |
Medicine (General) R5-920 Stephen P Myers Joan O’Connor J Helen Fitton et al. A combined phase I and II open label study on the effects of a seaweed extract nutrient complex on osteoarthritis |
| description |
Stephen P Myers1,2, Joan O’Connor1,2, J Helen Fitton3, Lyndon Brooks4, Margaret Rolfe4, Paul Connellan5, Hans Wohlmuth2,5,6, Phil A Cheras1,2, Carol Morris51NatMed-Research, 2Centre for Health and Wellbeing, 4Graduate Research College, 5Centre for Phytochemistry and Pharmacology, 6Medicinal Plant Herbarium, Southern Cross University, Lismore, NSW, Australia; 3Marinova Pty Ltd, Hobart, Tasmania, AustraliaBackground: Isolated fucoidans from brown marine algae have been shown to have a range of anti-inflammatory effects.Purpose: This present study tested a Maritech® extract formulation, containing a blend of extracts from three different species of brown algae, plus nutrients in an open label combined phase I and II pilot scale study to determine both acute safety and efficacy in osteoarthritis of the knee. Patients and methods: Participants (n = 12, five females [mean age, 62 ± 11.06 years] and seven males [mean age, 57.14 ± 9.20 years]) with a confirmed diagnosis of osteoarthritis of the knee were randomized to either 100 mg (n = 5) or 1000 mg (n = 7) of a Maritech® extract formulation per day. The formulation contained Maritech® seaweed extract containing Fucus vesiculosis (85% w/w), Macrocystis pyrifera (10% w/w) and Laminaria japonica (5% w/w) plus vitamin B6, zinc and manganese. Primary outcome was the average comprehensive arthritis test (COAT) score which is comprised of four sub-scales: pain, stiffness, difficulty with physical activity and overall symptom severity measured weekly. Safety measures included full blood count, serum lipids, liver function tests, urea, creatinine and electrolytes determined at baseline and week 12. All adverse events were recorded.Results: Eleven participants completed 12 weeks and one completed 10 weeks of the study. Using a multilevel linear model, the average COAT score was reduced by 18% for the 100 mg treatment and 52% for the 1000 mg dose at the end of the study. There was a clear dose response effect seen between the two treatments (P ≤ 0.0005) on the average COAT score and each of the four COAT subscales (pain, stiffness, difficulty with physical activity and overall symptom severity) (P ≤ 0.05). The preparation was well tolerated and the few adverse events were unlikely to be related to the study medication. There were no changes in blood parameters measured over the course of the study with the exception of an increase in serum albumin which was not clinically significant.Conclusion: The seaweed extract nutrient complex when taken orally over twelve weeks decreased the symptoms of osteoarthritis in a dose-dependent manner. It was demonstrated to be safe to use over the study period at the doses tested. The efficacy of the preparation now needs to be demonstrated in a phase III randomized controlled trial (RCT). Australian and New Zealand Clinical Trials Register: ACTRN12607000229471. Keywords: fucoidan, osteoarthritis, complementary medicine, inflammation, TNF alpha |
| format |
article |
| author |
Stephen P Myers Joan O’Connor J Helen Fitton et al. |
| author_facet |
Stephen P Myers Joan O’Connor J Helen Fitton et al. |
| author_sort |
Stephen P Myers |
| title |
A combined phase I and II open label study on the effects of a seaweed extract nutrient complex on osteoarthritis |
| title_short |
A combined phase I and II open label study on the effects of a seaweed extract nutrient complex on osteoarthritis |
| title_full |
A combined phase I and II open label study on the effects of a seaweed extract nutrient complex on osteoarthritis |
| title_fullStr |
A combined phase I and II open label study on the effects of a seaweed extract nutrient complex on osteoarthritis |
| title_full_unstemmed |
A combined phase I and II open label study on the effects of a seaweed extract nutrient complex on osteoarthritis |
| title_sort |
combined phase i and ii open label study on the effects of a seaweed extract nutrient complex on osteoarthritis |
| publisher |
Dove Medical Press |
| publishDate |
2010 |
| url |
https://doaj.org/article/1b3fb350814c4649a4fcf61fe7e88109 |
| work_keys_str_mv |
AT stephenpmyers acombinedphaseiandiiopenlabelstudyontheeffectsofaseaweedextractnutrientcomplexonosteoarthritis AT joanoamprsquoconnor acombinedphaseiandiiopenlabelstudyontheeffectsofaseaweedextractnutrientcomplexonosteoarthritis AT jhelenfitton acombinedphaseiandiiopenlabelstudyontheeffectsofaseaweedextractnutrientcomplexonosteoarthritis AT etal acombinedphaseiandiiopenlabelstudyontheeffectsofaseaweedextractnutrientcomplexonosteoarthritis AT stephenpmyers combinedphaseiandiiopenlabelstudyontheeffectsofaseaweedextractnutrientcomplexonosteoarthritis AT joanoamprsquoconnor combinedphaseiandiiopenlabelstudyontheeffectsofaseaweedextractnutrientcomplexonosteoarthritis AT jhelenfitton combinedphaseiandiiopenlabelstudyontheeffectsofaseaweedextractnutrientcomplexonosteoarthritis AT etal combinedphaseiandiiopenlabelstudyontheeffectsofaseaweedextractnutrientcomplexonosteoarthritis |
| _version_ |
1718403600834625536 |